Laxative Use in Inpatients on Oxycodone/Naloxone Prolonged Release and Oxycodone Prolonged Release for Cancer and Non-cancer Pain

References

• Purdue Pharma. Targin® (Oral Oxycodone/Naloxone Prolonged-release Tablet) Now launching across Europe to control severe chronic pain with significantly reduced risk of opioid-induced constipation [press release]. 2009. [accessed 2018 Feb 01] http://evaluategroup.com/Universal/View.aspx?type=Story&id=230600.
   Google Scholar
• Vondrackova D, Leyendecker P, Meissner W, et al. Analgesic efficacy and safety of Oxycodone in combination with naloxone as prolonged release tablets in patients with moderate to severe chronic pain. J Pain. 2008;9(12):1144–54. doi: 10.1016/j.jpain.2008.06.014.
   PubMed Web of Science ®Google Scholar
• Schuster BG, Kosar L, Kamrul R. Constipation in older adults: stepwise approach to keep things moving. Can Fam Physician. 2015;61(2):152–8.
   PubMed Web of Science ®Google Scholar
• Ward A, Del Campo M, Hauser K. Complications with Oxycodone and naloxone. Aust Prescr. 2017;40(4):156–157.
   PubMed Web of Science ®Google Scholar
• Ballantyne JC, Kalso E, Stannard C. WHO analgesic ladder: a good concept gone astray. BMJ. 2016;352:i20
   PubMedGoogle Scholar
• Karanges EA, Blanch B, Buckley NA, Pearson SA. Twenty-five years of prescription opioid use in Australia: a whole-of-population analysis using pharmaceutical claims. Br J Clin Pharmacol. 2016;82(1):255–67.
   PubMed Web of Science ®Google Scholar
• British Pain Society. Opioids for persistent pain: summary of guidance on good practice from the British Pain Society. Br J Pain. 2012;6(1):9–10.
   PubMedGoogle Scholar
• Busse JW, Craigie S, Juurlink DN, et al. Guideline for opioid therapy and chronic noncancer pain. CMAJ. 2017;189(18):E659–EE66.
   PubMed Web of Science ®Google Scholar
• Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain–United States, 2016. JAMA. 2016;315(15):1624–1645. doi: 10.1001/jama.2016.1464.
   PubMed Web of Science ®Google Scholar
• Burness CB, Keating GM. Oxycodone/naloxone prolonged-release: a review of its use in the management of chronic pain while counteracting opioid-induced constipation. Drugs. 2014;74(3):353–75.
   PubMed Web of Science ®Google Scholar
• Candy B, Jones L, Larkin PJ, Vickerstaff V, Tookman A, Stone P. Laxatives for the management of constipation in people receiving palliative care. Cochrane Database Syst Rev. 2015;(5). Art. No.: CD003448. doi: 10.1002/14651858.CD003448.pub4
   Web of Science ®Google Scholar
• Gyawali B, Hayashi N, Tsukuura H, Honda K, Shimokata T, Ando Y. Opioid-induced constipation. Scand J Gastroenterol. 2015;50(11):1331–38.
   PubMed Web of Science ®Google Scholar
• Prichard D, Norton C, Bharucha AE. Management of opioid-induced constipation. Br J Nurs. 2016;25(10):S4–S11.
   PubMedGoogle Scholar
• Badke A, Rosielle DA. Opioid-Induced Constipation Part 2: Newer Therapies #295. J Palliat Med. 2015;18(10):893–894.
   PubMed Web of Science ®Google Scholar
• Stein C. Opioid receptors. Annu Rev Med. 2016;67(1):433–51.
   PubMedGoogle Scholar
• Lowenstein O, Leyendecker P, Hopp M, et al. Combined prolonged-release Oxycodone and naloxone improves bowel function in patients receiving opioids for moderate-to-severe non-malignant chronic pain: a randomised controlled trial. Expert Opin Pharmacother. 2009;10(4):531–43. doi: 10.1517/14656560902796798.
   PubMed Web of Science ®Google Scholar
• Meissner W, Leyendecker P, Mueller-Lissner S, et al. A randomised controlled trial with prolonged-release oral oxycodone and naloxone to prevent and reverse opioid-induced constipation. Eur J Pain. 2009;13(1):56–64. doi: 10.1016/j.ejpain.2008.06.012.
   PubMed Web of Science ®Google Scholar
• Simpson K, Leyendecker P, Hopp M, et al. Fixed-ratio combination Oxycodone/naloxone compared with Oxycodone alone for the relief of opioid-induced constipation in moderate-to-severe noncancer pain. Curr Med Res Opin. 2008;24(12):3503–12. doi: 10.1185/03007990802584454.
   PubMed Web of Science ®Google Scholar
• Ducrotte P, Causse C. The Bowel Function Index: a new validated scale for assessing opioid-induced constipation. Curr Med Res Opin. 2012;28(3):457–466.
   PubMed Web of Science ®Google Scholar
• Rentz AM, Yu R, Muller-Lissner S, Leyendecker P. Validation of the Bowel Function Index to detect clinically meaningful changes in opioid-induced constipation. J Med Econ. 2009;12(4):371–83. doi: 10.3111/13696990903430481.
   PubMedGoogle Scholar
• Cuomo A, Russo G, Esposito G, Forte CA, Connola M, Marcassa C. Efficacy and gastrointestinal tolerability of oral Oxycodone/naloxone combination for chronic pain in outpatients with cancer. Am J Hosp Palliat Care. 2014;31(8):867–876. doi: 10.1177/1049909113510058.
   PubMed Web of Science ®Google Scholar
• Ahmedzai SH, Nauck F, Bar-Sela G, Bosse B, Leyendecker P, Hopp M. A randomized, double-blind, active-controlled, double-dummy, parallel-group study to determine the safety and efficacy of Oxycodone/naloxone prolonged-release tablets in patients with moderate/severe, chronic cancer pain. Palliat Med. 2012;26(1):50–60. doi: 10.1177/0269216311418869.
   PubMed Web of Science ®Google Scholar
• Jemal A, Center MM, DeSantis C, Ward EM. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev. 2010;19(8):1893–907. doi: 10.1158/1055-9965.EPI-10-0437.
   PubMed Web of Science ®Google Scholar
• Singal AK, Anand BS. Recent trends in the epidemiology of alcoholic liver disease. Clin Liver Dis. 2013;2(2):53–6. doi: 10.1002/cld.168.
   Google Scholar
• Loomba R, Sanyal AJ. The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol. 2013;10(11):686–90.
   PubMed Web of Science ®Google Scholar
• Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–383.
   PubMedGoogle Scholar
• Clinical Excellence Commission. Leading better value care; Falls prevention in hospitals. NSW Government, 2012. [accessed 2018 Feb 01] http://www.cec.health.nsw.gov.au/patient-safety-programs/adult-patient-safety/falls-prevention/falls-prevention-in-hospitals/risk-screening
   Google Scholar
• Dupoiron D, Stachowiak A, Loewenstein O, et al. A phase III randomized controlled study on the efficacy and improved bowel function of prolonged-release (PR) Oxycodone-naloxone (up to 160/80 mg daily) vs Oxycodone PR. Eur J Pain. 2017;21(9):1528–37. doi: 10.1002/ejp.1054.
   PubMed Web of Science ®Google Scholar